Evidence map›Paper›PMID 37097768›Full record

ArticleAge and ageing2023

Prediabetes, diabetes and loss of disability-free survival in a community-based older cohort: a post-hoc analysis of the ASPirin in Reducing Events in the Elderly trial.

Zhen Zhou, Andrea J Curtis, Alice Owen, Rory Wolfe, Anne M Murray, Andrew M Tonkin, Michael E Ernst, Suzanne G Orchard, Chao Zhu, Prudence R Carr and 8 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Age and ageing, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 2 countries.

Zhen ZhouSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Andrea J CurtisSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Alice OwenSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Rory WolfeSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Anne M MurrayDivision of Geriatrics, Department of Medicine Hennepin HealthCare, Berman Centre for Outcomes and Clinical Research, Hennepin Healthcare Research Institute, Minneapolis, MN, USA.
Andrew M TonkinSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Michael E ErnstDepartment of Pharmacy Practice and Science, College of Pharmacy, The University of Iowa, Iowa, IA, USA.
Suzanne G OrchardSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Chao ZhuDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Prudence R CarrSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Christopher M ReidSchool of Public Health, Curtin University, Perth, WA, Australia.
Sara E EspinozaSam and Ann Barshop Institute, UT Health San Antonio, San Antonio, TX, USA.
Raj C ShahDepartment of Family and Preventive Medicine, The Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.
Robyn L WoodsSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Joanne RyanSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
John J McNeilSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Mark R NelsonMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Sophia ZoungasSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Monash University · AUUniversity of Tasmania · AUBerman Center for Outcomes and Clinical Research · USCurtin University · AURush University Medical Center · USSouth Texas Veterans Health Care System · USUniversity of Iowa · US

Funding

ASPirin in Reducing Events in the ElderlyU01AG029824 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI MCNEIL, JOHN JAMES, MURRAY, ANNE M · 2009 to 2018
$64.6M
Main Administrative CoreU19AG062682 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI MURRAY, ANNE M · 2019 to 2023
$42.9M
NIA NIH HHS U01 AG029824NIA NIH HHS U19 AG062682
6 · The paper itself

Abstract

backgroundEvidence for the prognostic implications of hyperglycaemia in older adults is inconsistent.

objectiveTo evaluate disability-free survival (DFS) in older individuals by glycaemic status.

methodsThis analysis used data from a randomised trial recruiting 19,114 community-based participants aged ≥70 years, who had no prior cardiovascular events, dementia and physical disability. Participants with sufficient information to ascertain their baseline diabetes status were categorised as having normoglycaemia (fasting plasma glucose [FPG] < 5.6 mmol/l, 64%), prediabetes (FPG 5.6 to <7.0 mmol/l, 26%) and diabetes (self-report or FPG ≥ 7.0 mmol/l or use of glucose-lowering agents, 11%). The primary outcome was loss of disability-free survival (DFS), a composite of all-cause mortality, persistent physical disability or dementia. Other outcomes included the three individual components of the DFS loss, as well as cognitive impairment-no dementia (CIND), major adverse cardiovascular events (MACE) and any cardiovascular event. Cox models were used for outcome analyses, with covariate adjustment using inverse-probability weighting.

resultsWe included 18,816 participants (median follow-up: 6.9 years). Compared to normoglycaemia, participants with diabetes had greater risks of DFS loss (weighted HR: 1.39, 95% CI 1.21-1.60), all-cause mortality (1.45, 1.23-1.72), persistent physical disability (1.73, 1.35-2.22), CIND (1.22, 1.08-1.38), MACE (1.30, 1.04-1.63) and cardiovascular events (1.25, 1.02-1.54) but not dementia (1.13, 0.87-1.47). The prediabetes group did not have an excess risk for DFS loss (1.02, 0.93-1.12) or other outcomes.

conclusionsAmong older people, diabetes was associated with reduced DFS, and higher risk of CIND and cardiovascular outcomes, whereas prediabetes was not. The impact of preventing or treating diabetes in this age group deserves closer attention.

Indexed as

Cardiovascular DiseasesDiabetes MellitusPrediabetic StateAgedAspirinHumansPrognosisAspirincardiovasculardiabetesdisabilitydisability-free survivalolderolder people

Identifiers

PMID37097768
PMCPMC10128162
OpenAlexW4366993003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.